Gaudium IVF Q4 FY26 earnings call: Revenue & Margins
Q4 FY26 earnings call: what management said on revenue, margins and capex.
- Revenue
- ₹30Cr
- +12.7% YoY
- Net profit
- ₹8Cr
- +29.4% YoY
- Margin
- 40.1%
- +7.7 pp YoY
Guidance rank: #20 of 34 in Healthcare Services
See the sector's top 10 — free with your mobile number.
The short version
Company plans rapid expansion: aiming to increase from 7 hubs to 19 hubs within 3 years. Gaudium IVF expects robust growth driven by rapid expansion: 10 new hubs in FY27, 8 in FY28, and 1 in FY29.
From Gaudium IVF's Q4 FY26 earnings-call transcript · updated 23 Sept 2026.
Revenue & Sales Performance
- Company plans rapid expansion: aiming to increase from 7 hubs to 19 hubs within 3 years.
- Revenue growth seen in FY26: INR 104.35 crore, a 47.56% increase from FY25.
- Volume growth: 2,255 ovum pickups (cycles) done in FY26; expected to increase with expansion.
- Growth driven by hub maturity, higher volume, and international patient influx (~25-30% contribution).
- Focus on AI-led embryology and SOP-driven process to maintain clinical excellence during scale-up.
- International hubs planned in key locations: Paris, Nigeria, Sydney to boost medical tourism.
2 more points from Gaudium IVF's call on revenue
Create a free account to keep reading this call
Profitability & Margins
See what Gaudium IVF said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- FY26 capital expenditure was approximately INR 2.11 crore.
- For FY27, expected capex is around INR 25 crore.
- Capex mainly for new hubs, estimated average cost of INR 2.5 crore per hub.
- Funding primarily from IPO proceeds and internal accruals.
- Plan to open 10 new hubs in FY27, 8 in FY28, and 1 in FY29.
- Strategy involves phased rollout deeper into Tier 2 markets with additional spokes.
- Asset-light hub and spoke model to enable capital-efficient scaling.
- No current plans to seek private equity; growth funded by IPO proceeds and internal resources.
2 more points from Gaudium IVF's call on capex
Create a free account to keep reading this call
Top-ranked in Healthcare Services
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Gaudium IVF said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
See what Gaudium IVF said on order book & pipeline — free account, 30 seconds.
Gaudium IVF — Quarterly revenue & net profit
Gaudium IVF Q4 FY26 results — key figures
| ₹ Cr | Q4 FY26 | Q4 FY25 | YoY | Q3 FY26 | QoQ |
|---|---|---|---|---|---|
| Revenue | 30 | 27 | +12.7% | 25 | +23.8% |
| Operating profit (EBITDA) | 12 | 9 | +39.6% | 7 | +85.5% |
| Operating margin | 40.1% | 32.39% | +7.7 pp | 26.76% | +13.3 pp |
| Profit before tax | 10 | 8 | +27.7% | 5 | +109.7% |
| Net profit (PAT) | 8 | 6 | +29.4% | 4 | +130.3% |
| EPS (₹) | 1.15 | 1.05 | +9.5% | 0.59 | +94.9% |
Source: reported quarterly figures (Screener), ₹ crore.
Reported quarterly figures (₹ Cr). Latest (Q1 FY27): revenue ₹19 Cr, net profit ₹2 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Gaudium IVF's management said in earlier quarters
Others in Healthcare Services this season
- Suven Life Sciences (Q4 FY26)
The provided pages of the investor presentation do not report any revenue, sales, or volume figures for the quarter. Key investor presentation takeaways from Su
- Invicta Diagnostic (Q4 FY26)
Invicta Diagnostic Limited is deploying IPO funds (INR 21 crores raised) primarily towards: . Key concall takeaways from Invicta Diagnostic's Q4 FY26 earnings…
- KMC Speciality (Q4 FY26)
Q4 FY’26 Revenue from Operations: INR 82.3 Cr, up 35.0% YoY from INR 60.9 Cr in Q4 FY’25 (Page 20) . Key concall takeaways from KMC Speciality Hospitals…
- Star Imaging (Q4 FY26)
Capex planned for FY27 is around INR 20 to 25 crores, mainly towards new centres and equipment. Key concall takeaways from Star Imaging's Q4 FY26 earnings call…
Potential multibaggers · Q2 FY27
Potential multibaggers in Healthcare Services
on management's own guidance
- Strong growth2
- Strong growth1
- Aster DM QualityGood growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Arthneeti Pro · Annual
Gaudium IVF and 15K+ more earnings calls,
for less than your morning chai
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Gaudium IVF Q4 FY26 results?
Company plans rapid expansion: aiming to increase from 7 hubs to 19 hubs within 3 years. Gaudium IVF expects robust growth driven by rapid expansion: 10 new hubs in FY27, 8 in FY28, and 1 in FY29.
What is Gaudium IVF share price analysis?
Gaudium IVF currently shows a neutral. The stock trades at a P/E of 36.5 with a market cap of ₹846 Cr. Investors should review the full earnings analysis for detailed insights.
Is Gaudium IVF planning capital expenditure?
FY26 capital expenditure was approximately INR 2.11 crore.
Keep Gaudium IVF on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.